Based on what I've read, I expect this stock to hit $2.00 soon.
In the Q3, GALE increased by nearly 70% and is currently hovering around the $1.90 range. Moving forward, I think GALE will be the best performing stock of this group in Q4. Not only has it traded higher on a consistent basis, and maintained its gains, but investors will be anticipating final data analysis of its Phase II trial, which should occur in the coming months. This data will provide a clear picture of what we may expect from its current Phase III trial. If encouraging, the final analysis could lead to Sunesis-like upside, as investors realize the true market potential of NeuVax. There's no reason to believe that final analysis will be discouraging seeing as how all other data has been incredible. To that end, if the data is strong, this stock could break into a new level.